Roche: Rozlytrek approved in two indications in Europe
(CercleFinance.com) - On Monday Roche announced that the European Commission has approved the marketing of its Rozlytrek therapy for the treatment of solid tumours with NTRK gene fusion.
This approval concerns pathologies as varied as sarcoma, pancreatic cancer and ovarian cancer, the laboratory said in a statement.
The Swiss biopharmaceutical group says that the Commission has also approved the marketing of Rozlytrek for the treatment of advanced ROS1-positive non-small cell lung cancer.
These approvals will enable the provision of tailored treatment options for patients with these relatively rare and difficult-to-treat cancers, Roche said.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
This approval concerns pathologies as varied as sarcoma, pancreatic cancer and ovarian cancer, the laboratory said in a statement.
The Swiss biopharmaceutical group says that the Commission has also approved the marketing of Rozlytrek for the treatment of advanced ROS1-positive non-small cell lung cancer.
These approvals will enable the provision of tailored treatment options for patients with these relatively rare and difficult-to-treat cancers, Roche said.
Copyright (c) 2020 CercleFinance.com. All rights reserved.